Chardan, a global investment bank, announced today that the peer-reviewed journal, Human Gene Therapy Clinical Development, published a perspective authored by analysts in the firm’s equity research department.
| NEW YORK, /PRNewswire/ -- Chardan, a global investment bank, announced today that the peer-reviewed journal, Human Gene Therapy Clinical Development, published a perspective authored by analysts in the firm’s equity research department. The article, entitled “Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies,” is the first in a three-part series focused on valuing in vivo gene therapy companies. The publication, led by Chardan’s Head of Healthcare Research, Dr. Gbola Amusa, CFA, focuses on the underpinnings of company valuation and why widely-used approaches are limited in valuing in vivo gene therapy companies. The report examines a case study on AveXis, a registration-stage gene therapy company acquired by Novartis, to illustrate points on the valuation of breakthrough innovations that will have broader applicability throughout the in vivo gene therapy space. “We’re examining different types of valuation methodologies that should help investors recognize the true potential of some of the most exciting emerging technologies the world has ever seen,” said Amusa. “Traditional valuation methods used across dozens of sectors have limitations when evaluating gene therapies and are a reason why many overlooked the potential of AveXis, our former top pick in the sector, before the company was acquired for $8.7 billion earlier this year, more than 14x its $600 million IPO valuation two years earlier.” Co-authoring the report and the team that works directly with Dr. Amusa for his genetic medicines coverage includes:
To receive a copy of the report please visit the publisher’s website for Human Gene Therapy. About Chardan Chardan is an independent global investment bank specializing in healthcare, SPACs and emerging growth companies. Our range of services includes capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc. Learn more about Chardan: www.chardan.com Company Contact: Media Contact:
SOURCE Chardan Capital Markets, LLC |
View original content:
